Key achievements in 2022
2022
January


Jyseleca® approved in UC in Great Britain
March


Jyseleca® approved in UC in Japan
April


Appointment of Dr. Paul Stoffels as CEO and Chairman
June


Expansion into oncology with acquisitions of CellPoint (NL) and AboundBio (US)
October


Positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies
November


New R&D strategy and fit-for-purpose organization
Initial encouraging results from FILOSOPHY real-world study of filgotinib in RA
CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors
December


Initial encouraging Phase 1/2 results for CD19 CAR-T in rrNHL manufactured at point-of-care
Set-up of new Management Committee and announced changes to the Executive Committee